Antimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Int J Colorectal Dis. 2020 Apr;35(4):595-606. doi: 10.1007/s00384-020-03535-9. Epub 2020 Mar 4.
Colon cancer is a great health concern worldwide, as it is the second leading cause of cancer-related death. Conventional treatment of cancer such as surgery, radiotherapy, and chemotherapy are faced with limitations and side effects. Therefore, strategies for the treatment of cancer need to be modified or new strategies replacing the old one.
The aim of this study is to review the role of bacteria or their products (such as peptides, bacteriocins, and toxins) as a therapeutic agent for colon cancer.
Recently, the therapeutic role of bacteria and their products in colon cancer treatment holds promise as emerging novel anti-cancer agents. Unlike the conventional treatments, targeted therapy based on the use of bacteria that are able to directly target tumor cells without affecting normal cells is evolving as an alternative strategy. Moreover, several bacterial species were used in live, attenuated or genetically modified that are able to multiply selectively in tumors and inhibiting their growth.
结肠癌是全球范围内的一个重大健康关注点,因为它是癌症相关死亡的第二大主要原因。癌症的常规治疗方法,如手术、放疗和化疗,都面临着局限性和副作用。因此,癌症治疗策略需要进行修改或用新的策略取代旧的策略。
本研究旨在综述细菌或其产物(如肽、细菌素和毒素)作为结肠癌治疗剂的作用。
最近,细菌及其产物在结肠癌治疗中的治疗作用作为新兴的新型抗癌药物具有广阔的前景。与传统治疗方法不同,基于使用能够直接靶向肿瘤细胞而不影响正常细胞的细菌的靶向治疗正在发展成为一种替代策略。此外,还使用了几种能够在肿瘤中选择性繁殖并抑制其生长的活的、减毒的或遗传修饰的细菌。